Shanghai Pharmaceuticals' (HKG:2607, SHA:601607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from China's National Medical Products Administration for its sitagliptin/metformin extended-release tablets, according to a Shanghai bourse filing on Thursday.
The drug was developed for the treatment of adult patients with type 2 diabetes mellitus.